BIOMARIN PHARMACEUTICAL INC
BMRNUS売上高
$3.2B
百万USD
営業利益
$409M
百万USD
純利益
$349M
百万USD
ROE
5.7%
最新FY
EPS
$1.80
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $486M | $17M | $0.09 |
| FY2021 | Q2 | $502M | $13M | $0.07 |
| FY2021 | Q3 | $409M | $-36M | $-0.20 |
| FY2021 | FY | $1.8B | $-64M | $-0.35 |
| FY2022 | Q1 | $519M | $121M | $0.63 |
| FY2022 | Q2 | $534M | $28M | $0.15 |
| FY2022 | Q3 | $505M | $-7M | $-0.04 |
| FY2022 | FY | $2.1B | $142M | $0.75 |
| FY2023 | Q1 | $596M | $51M | $0.27 |
| FY2023 | Q2 | $595M | $56M | $0.29 |
| FY2023 | Q3 | $581M | $40M | $0.21 |
| FY2023 | FY | $2.4B | $168M | $0.87 |
| FY2024 | Q1 | $649M | $89M | $0.46 |
| FY2024 | Q2 | $712M | $107M | $0.55 |
| FY2024 | Q3 | $746M | $106M | $0.55 |
| FY2024 | FY | $2.9B | $427M | $2.21 |
| FY2025 | Q1 | $745M | $186M | $0.95 |
| FY2025 | Q2 | $825M | $241M | $1.23 |
| FY2025 | Q3 | $776M | $-31M | $-0.16 |
| FY2025 | FY | $3.2B | $349M | $1.80 |
| FY2026 | Q1 | $766M | $106M | $0.54 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $1.5B | $1.7B | $1.9B | $1.8B | $2.1B | $2.4B | $2.9B | $3.2B |
| 営業利益 | $-803M | $-15M | $-124M | $-100M | $-37M | $-82M | $150M | $158M | $484M | $409M |
| 純利益 | $-630M | $-117M | $-77M | $-24M | $859M | $-64M | $142M | $168M | $427M | $349M |
| 総資産 | $4.0B | $4.6B | $4.4B | $4.7B | $5.8B | $6.0B | $6.4B | $6.8B | $7.0B | $7.6B |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $2.8B | $2.8B | $3.0B | $3.1B | $4.1B | $4.3B | $4.6B | $5.0B | $5.7B | $6.1B |
| 営業CF | - | - | $20M | $48M | $85M | $305M | $176M | $159M | $573M | $828M |
| EPS | $-3.81 | $-0.67 | $-0.44 | $-0.13 | $4.53 | $-0.35 | $0.75 | $0.87 | $2.21 | $1.80 |
| BPS | $16.00 | $15.95 | $16.64 | $17.35 | $22.58 | $23.21 | $24.68 | $26.24 | $29.66 | $31.65 |
| ROE | -22.8% | -4.2% | -2.6% | -0.8% | 20.9% | -1.5% | 3.1% | 3.4% | 7.5% | 5.7% |